Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWABIMS Follow-up: Atorvastatin + Interferon-Beta 1b in RRMS
NCT01111656Phase 2Completed
- Sponsor
- Insel Gruppe
- Start
- Mar 2007
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Atorva in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Insel Gruppe. Primary endpoint: Proportion of patients with new lesions on T2-weighted images at 12 months. Started Mar 2007; status: completed.
02
Drugs
Atorva
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01111656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111656.